If You Invested in Bio Green Med Solution Inc (BGMS)

Bio Green Med Solution, Inc. (NASDAQ: BGMS) is described as a diversified company that, as of September 2025, has shifted its operations to focus on the provision of fire safety protection and distribution activities. According to its public disclosures, the company completed the acquisition of FITTERS Sdn. Bhd., a Malaysia-based group specializing in fire protection products and services, and now derives product revenue from the sales and distribution of fire safety equipment. The company is headquartered in Malaysia and its common stock is listed on The Nasdaq Capital Market under the symbol BGMS, with a 6% Convertible Exchangeable Preferred Stock listed under the symbol BGMSP.

Bio Green Med Solution, Inc. notes that it was formerly engaged in the biopharmaceutical industry under the name Cyclacel Pharmaceuticals, Inc. Prior to its strategic shift, the business was described as a clinical-stage biopharmaceutical company developing targeted medicines for cancer and other proliferative diseases, including programs focused on CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors, with pipeline candidates such as fadraciclib and plogosertib. In October 2025, the company entered into an Asset Purchase Agreement to sell certain assets, including all patent rights related to plogosertib, a PLK1 inhibitor for the treatment of advanced cancers and hematological malignancies.

The company’s public filings indicate that research and development expenses for the three months ended September 30, 2025 were zero, following the liquidation of its UK subsidiary, Cyclacel Limited, and the cessation or pausing of its prior research and development programs. As a result, Bio Green Med Solution, Inc. is now primarily described as focusing on commercial activities related to fire safety protection and distribution, rather than on internal drug development.

Bio Green Med Solution, Inc. has also reported capital markets and corporate actions that affect its equity structure. In July 2025, the company implemented a one-for-fifteen reverse stock split of its common stock, effective on July 7, 2025, with the stated aim of meeting the share bid price requirements of The Nasdaq Capital Market. In addition, the company has entered into multiple Warrant Exchange Agreements with accredited investors, under which existing warrants to purchase common stock were exchanged for newly issued shares of common stock. These transactions were disclosed in Form 8-K filings and were completed under exemptions from registration under the Securities Act of 1933.

The company’s preferred stock has been the subject of a Nasdaq listing compliance notice. In September 2025, Bio Green Med Solution, Inc. reported receiving a letter from Nasdaq stating that its 6% Convertible Exchangeable Preferred Stock, trading under the symbol BGMSP, no longer met the minimum Market Value of Publicly Held Shares requirement of $1 million under Nasdaq Listing Rule 5460(a)(2). The notice provided a period of 180 calendar days for the company to regain compliance, during which the preferred stock would continue to trade on the Nasdaq Capital Market. The company disclosed that this notice did not affect the listing of its common stock under the symbol BGMS.

Corporate governance disclosures show that the company has adjusted its board composition and committee assignments. In September 2025, an independent director resigned from the Board of Directors, and a new independent director was appointed to fill the vacancy. The Board also approved committee assignments for the Audit Committee, Compensation and Organization Committee, and Nominating and Governance Committee, and determined that certain directors satisfy the requirements of financial literacy and audit committee independence under applicable SEC rules and Nasdaq listing standards.

Bio Green Med Solution, Inc. has also communicated dividend practices related to its preferred stock. In October 2025, the Board of Directors declared a quarterly cash dividend on the company’s 6% Convertible Exchangeable Preferred Stock, payable to preferred stockholders of record as of a specified record date. This reflects the company’s ongoing obligations and practices with respect to its preferred equity securities as disclosed in its Form 8-K filings.

The company’s name and branding have evolved alongside its strategic transition. Public filings describe that Bio Green Med Solution, Inc. was formerly known as Cyclacel Pharmaceuticals, Inc., and that the company updated its logo to coincide with its new name and ticker symbol. An amended Form 8-K filed in September 2025 notes that the amendment was made to correct the logo on the cover page, and confirms the connection between the former name and the current Bio Green Med Solution, Inc. identity.

According to its own description, Bio Green Med Solution, Inc. is focused on advancing opportunities across its current business sectors while emphasizing long-term value creation for shareholders. Its disclosures highlight the transition from a clinical-stage biopharmaceutical focus to a business centered on fire safety protection products, services, and distribution, anchored by its acquisition of FITTERS Sdn. Bhd. and its operations based in Malaysia.

Business Evolution and Strategic Focus

Historically, the company’s activities were concentrated in the development of anticancer drugs that act on the cell cycle, including CDK and PLK inhibitors. The pipeline included programs such as fadraciclib and plogosertib, and the company reported that it derived revenue from the United Kingdom in connection with its prior biopharmaceutical operations. Following the liquidation of its UK subsidiary and the sale of patent rights related to plogosertib, the company’s disclosures emphasize its repositioning as a diversified company with primary emphasis on fire safety protection and distribution.

The acquisition of FITTERS Sdn. Bhd. is central to this repositioning. Public information states that FITTERS Sdn. Bhd. is a Malaysia-based group specializing in fire protection products and services, and that upon completion of the share exchange transaction, FITTERS Sdn. Bhd. became a wholly-owned subsidiary of Bio Green Med Solution, Inc. The company now reports product revenue from the sales and distribution of fire safety equipment following this acquisition.

Capital Markets and Listing Information

Bio Green Med Solution, Inc.’s common stock trades on The Nasdaq Capital Market under the symbol BGMS, and its 6% Convertible Exchangeable Preferred Stock trades under the symbol BGMSP. The company has disclosed actions taken to address Nasdaq listing requirements, including the reverse stock split of its common stock and its monitoring of the market value of publicly held shares of its preferred stock in response to a Nasdaq deficiency notice. These disclosures provide context for investors tracking the company’s equity structure and listing status.

Corporate Identity and Governance

The company’s transition from Cyclacel Pharmaceuticals, Inc. to Bio Green Med Solution, Inc. is documented in its SEC filings, which refer to the former name and note the adoption of a new logo aligned with the new corporate identity. Governance updates, such as changes in board composition and committee assignments, are disclosed in detail, including the appointment of independent directors and confirmation of their independence and financial literacy under Nasdaq and SEC standards.

Sector Classification

While the company is classified under the pharmaceutical preparations sector based on historical activities, its own recent description emphasizes that it is now a diversified company focused on fire safety protection and distribution activities. This dual context is relevant for users reviewing historical biopharmaceutical information alongside the company’s current operational focus in fire protection products, services, and equipment distribution.